Independence Bank of Kentucky Boosts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Independence Bank of Kentucky boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 42.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 580 shares of the medical research company’s stock after acquiring an additional 174 shares during the quarter. Independence Bank of Kentucky’s holdings in IQVIA were worth $102,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of IQV. American National Bank & Trust bought a new position in shares of IQVIA in the 1st quarter worth $26,000. ST Germain D J Co. Inc. raised its position in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the 4th quarter worth $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA in the 4th quarter worth $44,000. Finally, Zions Bancorporation N.A. raised its position in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on IQV. JPMorgan Chase & Co. reduced their price target on IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a research report on Monday, May 19th. Redburn Partners set a $188.00 target price on IQVIA in a research report on Friday, May 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Citigroup reaffirmed a “neutral” rating on shares of IQVIA in a research report on Thursday, May 22nd. Finally, Mizuho reduced their target price on IQVIA from $210.00 to $190.00 and set an “outperform” rating on the stock in a research report on Thursday, May 15th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $226.32.

IQVIA Stock Up 3.2%

Shares of IQV opened at $152.07 on Monday. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $26.31 billion, a price-to-earnings ratio of 20.28, a PEG ratio of 1.99 and a beta of 1.28. The stock’s 50-day moving average price is $147.69 and its 200-day moving average price is $178.90.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.54 earnings per share. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.